RSS Amplifier

Blog

Dyno Therapeutics

Building high-performance genetic technologies that enable genetic agency

dynotx.substack.comSource feed ↗10 posts

Live Last read · last published · next check

Written by

This blog elsewhere

Latest posts

Genetic medicine is about to be transformed by the agent economy

The modular nature of genetic medicine is particularly suitable for agentic work.

Claude Mythos Preview matches the best humans in solving Dyno’s sequence design challenge

At Dyno, we believe the future of biology will be shaped by AI systems that can reason about sequence, structure, and function at once to ultimately help design therapies with precision in vivo. For a decade, we’ve had a front seat in seeing how our ability to model and test new sequence designs has improved. Biological sequence models have become far more sophisticated since we started working on…

Dyno Psi-Phi: Shaping new futures for protein design

The promise of doing protein design with AI models is to do in one shot on a computer what would take months or even years of trial and error in the lab.

Cultivating an ecosystem of trust through principled decision-making

How Dyno’s unconventional partnership success principles cultivate an ecosystem of trust for gene therapy developers

Can AI agents solve the “last mile” problem in generative therapeutic design?

How agentic AI systems, aligned with the goal of curing genetic disease, can accelerate genetic agency

A Computational LEAP over an In vivo Experiment

As 2024 comes to a close, I look back at one of Dyno’s most exciting technical developments.

Dyno is scaling gene therapy research with cloud-native tools like Argo Workflows and Hera

Cloud native tools such as Kubernetes and Argo Workflows are improving productivity, accelerating innovation, and increasing operational efficiency.

Introduction to AAV as a Gene Therapy Vector, Part 2

Introduction

Introduction to AAV as a Gene Therapy Vector, Part 1

In two previous posts, we introduced gene therapy, a method for curing genetic diseases by providing healthy copies of defective genes, and Adeno-associated virus (AAV) capsids, the gene therapy delivery system Dyno focuses on.

Delivering an experience our AAViators expect through Agile work practices

This is easy to say but impossible to do without innovating on how biotech companies approach work.